The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of neural transmission

• Publication date

  2016-04-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00702-016-1552-3PMID 27098667PMCID PMC4939803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• O 1-7-4-2 Abnormal autophagy / lysosome function may play some role in Parkinson ’ s disease

  2018cited by this paper
• Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus

  2015cited by this paper
• Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals

  2015cited by this paper
• The microtubule associated protein tau H1 haplotype and risk of essential tremor

  2014cited by this paper
• OF GENETICS.

  2014cited by this paper
• Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels

  2014cited by this paper
• Clinical subtypes in Parkinson’s disease: the impact of MAPT haplotypes

  2014cited by this paper
• Primary age-related tauopathy (PART): a common pathology associated with human aging

  2014cited by this paper
• Variation in tau isoform expression in different brain regions and disease states.

  2013cited by this paper
• MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies.

  2013influential reference
• Neuropathology of dementia in a large cohort of patients with Parkinson's disease.

  2013cited by this paper
• Neuropathologic substrates of Parkinson disease dementia

  2012cited by this paper
• Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2

  2012cited by this paper
• The MAPT H1 haplotype is associated with tangle-predominant dementia

  2012cited by this paper
• MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies

  2012cited by this paper
• An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology

  2012cited by this paper
• Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

  2011cited by this paper
• Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy

  2011cited by this paper
• Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes.

  2011cited by this paper
• The Genetics of Parkinson Disease

  2010cited by this paper
• Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline

  2010cited by this paper
• Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease

  2009cited by this paper
• The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

  2009cited by this paper
• Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus.

  2008cited by this paper
• Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease.

  2007cited by this paper
• Haplotype-specific expression of exon 10 at the human MAPT locus.

  2006cited by this paper
• Genetics of Parkinson disease

  2004cited by this paper
• Colocalization of Tau and Alpha‐Synuclein Epitopes in Lewy Bodies

  2003influential reference
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.

  1999influential reference
• Association of an extended haplotype in the tau gene with progressive supranuclear palsy.

  1999cited by this paper
• An Improved Approach to Prepare Human Brains for Research

  1995cited by this paper
• Staging of Alzheimer's disease-related neurofibrillary changes.

  1995cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper

• Fibril treatment changes protein interactions of tau and α-synuclein in human neurons

  2023cites this paper
• Internetwork Connectivity Predicts Cognitive Decline in Parkinson’s and Is Altered by Genetic Variants

  2022cites this paper
• Polymorphism of neurodegeneration-related genes associated with Parkinson’s disease risk

  2022cites this paper
• APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease

  2021cites this paper
• iPS Cell-Based Model for MAPT Haplotype as a Risk Factor for Human Tauopathies Identifies No Major Differences in TAU Expression

  2021cites this paper
• Semantic Recollection in Parkinson’s Disease: Functional Reconfiguration and MAPT Variants

  2021influential citation
• Tau and MAPT genetics in tauopathies and synucleinopathies.

  2021cites this paper
• Self-Therapeutic Nanoparticle That Alters Tau Protein and Ameliorates Tauopathy Toward a Functional Nanomedicine to Tackle Alzheimer's.

  2020cites this paper
• The role of monogenic genes in idiopathic Parkinson's disease.

  2019cites this paper
• Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders

  2019cites this paper
• Intercepting Parkinson disease non-motor subtypes: A proof-of-principle study in a clinical setting.

  2018cites this paper
• MAPT as pathogenic risk factor for Parkinson's Disease

  2017cites this paper
• Regional Overlap of Pathologies in Lewy Body Disorders

  2017cites this paper